Coordinated regulation of the immunoproteasome subunits by PML/RARα and PU.1 in acute promyelocytic leukemia (Q42440049)

31 October 2017

Coordinated regulation of the immunoproteasome subunits by PML/RARα and PU.1 in acute promyelocytic leukemia (English)

1 reference

31 October 2017

1 reference

X-W Yang

1

1 reference

31 October 2017

P Wang

2

1 reference

31 October 2017

J-Q Liu

3

1 reference

31 October 2017

H Zhang

4

1 reference

31 October 2017

W-D Xi

5

1 reference

31 October 2017

X-H Jia

6

1 reference

31 October 2017

K-K Wang

7

1 reference

31 October 2017

language of work or name

English

0 references

publication date

17 June 2013

1 reference

31 October 2017

1 reference

31 October 2017

33

1 reference

31 October 2017

2700-2708

1 reference

31 October 2017

21

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2013.224

31 October 2017

0 references

cites work

The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

Transcriptional regulation in acute promyelocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

Acute promyelocytic leukemia: from highly fatal to highly curable

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

The PML-retinoic acid receptor alpha translocation converts the receptor from an inhibitor to a retinoic acid-dependent activator of transcription factor AP-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

PML/RARalpha targets promoter regions containing PU.1 consensus and RARE half sites in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

Potentiation of GATA-2 activity through interactions with the promyelocytic leukemia protein (PML) and the t(15;17)-generated PML-retinoic acid receptor alpha oncoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

Multimeric complexes of the PML-retinoic acid receptor alpha fusion protein in acute promyelocytic leukemia cells and interference with retinoid and peroxisome-proliferator signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

Chromatin modifications induced by PML-RARalpha repress critical targets in leukemogenesis as analyzed by ChIP-Chip

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

MHC class I antigens and immune surveillance in transformed cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

Functions of the proteasome in antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

Degradation of cell proteins and the generation of MHC class I-presented peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

Antigen-processing machinery breakdown and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

Proto-oncogene PML controls genes devoted to MHC class I antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

The significance of low PU.1 expression in patients with acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

Gene expression profiling of pediatric acute myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

Tumor necrosis factor-alpha induces coordinated changes in major histocompatibility class I presentation pathway, resulting in increased stability of class I complexes at the cell surface

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

PU.1 (Sfpi1), a pleiotropic regulator expressed from the first embryonic stages with a crucial function in germinal progenitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

Surprising new roles for PU.1 in the adaptive immune response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

The key role of PU.1/SPI-1 in B cells, myeloid cells and macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

Gamma-IFN induces a differential expression of HLA-DR, DQ and DP antigens on peripheral blood myeloid leukemic blasts at various stages of differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

In vitro growth response to G-CSF and GM-CSF by bone marrow cells of patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

A tight cluster of five unrelated human genes on chromosome 16q22.1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

Inhibition of growth and induction of apoptosis by all-trans retinoic acid in lymphoid cell lines transfected with the PML/RAR alpha fusion gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

Retinoic acid receptors, hematopoiesis and leukemogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

Cytokine-regulated expression of survivin in myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

ID1 and ID2 are retinoic acid responsive genes and induce a G0/G1 accumulation in acute promyelocytic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

Regulation of the hematopoietic cell kinase (HCK) by PML/RARα and PU.1 in acute promyelocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

Frequent antibody production against RARalpha in both APL mice and patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

PU.1, a shared transcriptional regulator of innate and adaptive immune cell fates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

The Transcription Factor PU.1 Controls Dendritic Cell Development and Flt3 Cytokine Receptor Expression in a Dose-Dependent Manner

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

Critical role of transcription factor PU.1 in the expression of CD80 and CD86 on dendritic cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.224

31 March 2020

Identifiers

DOI

10.1038/ONC.2013.224

1 reference

Dimensions Publication ID

31 October 2017

0 references

1 reference